



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61F 2/06	A1	(11) International Publication Number: WO 99/17683 (43) International Publication Date: 15 April 1999 (15.04.99)
(21) International Application Number: PCT/US98/17310 (22) International Filing Date: 20 August 1998 (20.08.98) (30) Priority Data: 08/944,313 6 October 1997 (06.10.97) US (71) Applicant: HEARTSTENT CORPORATION [US/US]; 651 Campus Drive, Saint Paul, MN 55112 (US). (72) Inventors: TWEDEN, Katherine, S.; 1175 Ashley Lane, Mahtomedi, MN 55115 (US). VANNEY, Guy, P.; 9809 Tyler Street, Blaine, MN 55434 (US). ODLAND, Thomas, L.; 6367 Deerwood Lane, Lino Lakes, MN 55014 (US). (74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: TRANSMYOCARDIAL IMPLANT		
(57) Abstract <p>The transmyocardial implant for establishing blood flow through the myocardium between a heart chamber and a lumen of a coronary vasculature includes a hollow rigid conduit extending between the lumen and the heart chamber. The conduit is formed of a rigid material to resist deformation in response to contraction of the myocardium and the conduit is resistant to thrombus. A tissue growth-inducing material is secured to an exterior of the conduit. The tissue growth-inducing material is positioned to discourage tissue growth over openings of the implant.</p> <div data-bbox="779 1144 1372 1953"> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TRANSMYOCARDIAL IMPLANT

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention pertains to an implant for directing blood flow directly
5 between a chamber of the heart and a coronary vasculature. More particularly, this
invention pertains to such an implant with an enhanced design for securing
placement of the implant.

2. Description of the Prior Art

International Patent Application No. PCT/US97/13980 filed August 12,
10 1997, entitled "Method and Apparatus for Performing Coronary Bypass Surgery",
and filed in the name of HeartStent Corporation, teaches an implant for defining a
blood flow conduit directly from a chamber of the heart to a lumen of a coronary
vasculature. An embodiment disclosed in the aforementioned application teaches an
L-shaped implant in the form of a rigid conduit having one leg sized to be received
15 within a lumen of a coronary artery and a second leg sized to pass through the
myocardium and extend into the left ventricle of the heart. As disclosed in the
above-referenced application, the conduit is rigid and remains open for blood flow to
pass through the conduit during both systole and diastole. The conduit penetrates
into the left ventricle in order to prevent tissue growth and occlusions over an
20 opening of the conduit.

It is an object of the present invention to provide an improved
transmyocardial implant with enhanced fixation structure.

SUMMARY OF THE INVENTION

According to a preferred embodiment of the present invention, a
25 transmyocardial implant is disclosed for establishing a blood flow path through a
myocardium between a heart chamber and a lumen of a coronary vasculature
residing on an exterior surface of the myocardium. The implant includes a hollow
rigid conduit with a first portion sized to be received within the lumen and with a
second portion sized to extend from the vasculature through the myocardium and
30 into the heart chamber. Open ends of the conduit define a blood flow pathway
within an interior of the conduit between the heart chamber and the lumen of the

vasculature. The conduit is formed of a material sufficiently rigid to resist deformation and closure of the pathway in response to contraction of the myocardium. Further, the conduit material is resistant to thrombus formation. A tissue growth-inducing material is secured to an exterior of the conduit.

5

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a side elevation view of an implant according to the present invention without showing a tissue growth-inducing material secured to an exterior of a conduit;

FIG. 1A is the view of FIG. 1 showing the implant of FIG. 1 and showing, in cross section, a tissue growth-inducing material secured to an exterior of the conduit and showing the implant positioned within the myocardium and lumen of a coronary vasculature;

FIG. 2 is the view of FIG. 1 showing a first alternative embodiment of a conduit;

FIG. 2A is the view of FIG. 1A with the embodiment of FIG. 2 showing a tissue growth-inducing material in cross section;

FIG. 3 is the view of FIG. 2 showing a modified external surface of a conduit;

FIG. 3A is the view of FIG. 2A incorporating the conduit of FIG. 3;

FIG. 4 is the view of FIG. 1 showing a fourth embodiment of the conduit;

FIG. 4A is the view of FIG. 1A with the embodiment of the conduit of FIG. 4 and showing a tissue growth-inducing material in cross section;

FIG. 5 is a side elevation view of the implant of FIG. 1A showing a tissue growth-inducing material secured to an exterior of the conduit of FIG. 1.

25

DESCRIPTION OF THE PREFERRED EMBODIMENT

With initial reference to FIG. 1, a conduit 10 is shown in the form of an L-shaped rigid tube. The conduit 10 may be formed of titanium or other rigid biocompatible material such as pyrolytic carbon or may be titanium which is coated with pyrolytic carbon. The material of the conduit 10 is preferably a rigid material in order to withstand contraction forces of the myocardium, as will be described. In the preferred embodiment, the tube will have an outside diameter D_o of about 3

millimeters and an internal diameter D_i of about 2 millimeters to provide a wall thickness of about .5 millimeters.

The tube 10 has a first portion 12 which is sized to be received within the lumen of a coronary vasculature such as the lumen 100 of a coronary artery 102 illustrated in FIG. 1A. As used in this application, the term "vasculature" refers to veins or arteries. The conduit 10 has a second portion 14 which extends at a right angle to the axis of portion 12. The second portion 14 is sized to extend from the coronary artery 102 directly through the myocardium 104 and protrude into the left ventricle 106 of a patient's heart. The second portion 14 is sized to have a length sufficient for the portion 14 to protrude into the left ventricle 106.

The first portion 12 has a first opening 16 and the second portion 14 has a second opening 18 in communication with an interior 20 of the implant 10. Therefore, blood can freely flow through the implant 10 between the left ventricle 106 and the lumen 100 of the coronary artery 102. A leading end 22 of the first portion 12 is provided with a smaller external diameter and with a beveled face to permit ease of insertion of the leading end 22 into the coronary artery.

As mentioned, the tube 10 is preferably formed of titanium or other smooth biocompatible material in order to resist thrombus formation on the surfaces of the conduit 10. Titanium is a presently preferred material due its long-term use in the cardiovascular industry. Further, titanium is sufficiently rigid to withstand deformation forces caused by contraction of the myocardium 104 to avoid deformation of the tube 10 so that the tube 10 remains open during both diastole and systole.

While tissue will adhere to titanium, the adhesion is inadequate when subjected to the shearing contracting forces of the myocardium due to the relative smoothness of extruded titanium. Therefore, a completed implant 50 is illustrated in FIGs. 1A and 5 and includes a sleeve 52 of tissue growth-inducing material secured to an exterior surface of the conduit 10.

As illustrated in FIGs. 1 and 1A, the second portion 14 includes two spaced-apart reduced-diameter portions 24, 26 to define grooves in the second portion 14. The sleeve 52 includes a first end 54 with sutures 56 disposed around end 54 to retain end 54 within the groove 24. The material at the first end 54 is folded over

the sutures 56 and stitched by stitching 58 to secure the first end 54 in the groove 24 and to immobilize the first end 54 relative to the tube 10. Similarly, a second end 60 of the sleeve 52 is retained by sutures 62 in the groove 26 and threading 64 secures the material of the sleeve 52 over the sutures 62. In the embodiments of FIGs. 1, 1A and 5, the sleeve 52 resides exclusively in the myocardium.

In the figures, the stitching 58,64 is shown exposed on an exterior of the sleeve 52. Alternatively, the sleeve 52 can be formed inverted so that the stitching 58,64 is not exposed.

Preferably, the sleeve 52 is formed of a fabric having biocompatible fibers defining interstitial spaces to receive tissue growth. An example of such a fabric is polyethylene terephthalate (such as polyester fabric sold by DuPont Company under the trademark Dacron). Such a fabric permits rapid tissue integration into the fabric thereby anchoring the fabric and, hence, the tube 10 to the patient's tissue. Also, the enlarged portions 62,54 resulting from folding the material of the sleeve over the sutures 62,56 enhances the volume of material susceptible to tissue integration, as well as providing a thickened area to further resist movement of the implant 50 relative to the myocardium 104. As a result, the sleeve 52 is selected to induce tissue attachment. Additionally, the first portion 12 is secured in place by means of a reduced-diameter groove 13 formed adjacent the leading end 22. With the reduced-diameter groove 13, a surgeon can place sutures 70 surrounding the coronary artery 102 to immobilize the coronary artery at the groove 13.

It is anticipated that tissue growth on and into the sleeve 52 could result in a buildup of tissue beyond the sleeve 52 to a thickness of about 1 millimeter. It is desirable that such tissue growth does not extend over ends 16, 18. Accordingly, the end 62 of the sleeve 52 is spaced from end 18 by a distance greater than an anticipated thickness of tissue growth extension beyond the sleeve 52. Since the anticipated thickness of tissue growth is about 1 millimeter, a minimum spacing of end 62 from tube end 18 of 1 millimeter is desired. However, a conservative additional spacing of 4-5 millimeters is preferred.

While a fabric tissue growth inducing material is illustrated, other materials could be used. For example, the tissue growth inducing material could be sintered metal on the external surface of the tube 10. Sintered metal results in a porous

surface to receive tissue growth. The area of the sintered metal will be spaced from ends 16, 18 to prevent tissue accumulation on the sintered area from growing over and blocking ends 16, 18.

FIGs. 2, 2A, 3, 3A, and 4, 4A show alternative embodiments of the present invention. In each of these embodiments, elements in common with those of FIGs. 1 and 1A are numbered identically and distinguished by letters "a", "b", and "c". Such elements will not be separately discussed with respect to the alternative embodiments except when necessary to distinguish between the embodiments.

In FIGs. 1 and 1A, the sleeve 52 resides exclusively in the myocardium 104. In the embodiment of FIGs. 2 and 2A, the groove 24a is moved to the intracoronary portion 12a such that the sleeve 52a resides in both the myocardium 104 and in the coronary artery 102 so that tissue growth can occur from the myocardium as well as the coronary artery 102 into the sleeve 52a. The embodiment of FIGs. 2 and 2A is a presently preferred embodiment to enhance fixation.

In the embodiments of FIGs. 3 and 3A, the exterior surface of the tube 10b is roughened as indicated by hatch marks 200 in both the first portion 12b and second portion 14b. The roughening can be in the form of a knurling or a roughened surface due to sandblasting or the application of sinter beads. When the Dacron sleeve 52b is placed over the roughened surface 200, the sleeve 52b is restricted from motion relative to the exterior surface of the tube 10b due to enhanced friction resulting from the roughening 200. In addition, the roughening 200 provides a roughened surface with protrusions and pitting, around which tissue may grow as part of the tissue growth into the sleeve 52a.

FIGs. 4 and 4A are similar to the embodiments of FIGs. 2 and 2A except that the groove 26c has been moved from end 18c by a further distance so that the sleeve 52c resides primarily in the coronary artery 102 and only partially into the myocardium 104.

In all the embodiments, the tissue growth-inducing material of the sleeve 52c remains spaced from ends 16, 18 by a distance sufficient to avoid tissue growth on the material of the sleeve from extending over and blocking the ends 16, 18. As mentioned, an anticipated extension of tissue growth beyond sleeve 52 is about 1 millimeter so that the ends 54,60 should be spaced from tube ends 16, 18 by a

minimum of 1 millimeter and preferably 4-5 millimeters to prevent tissue growth over ends 16, 18.

5 Having disclosed the present invention in a preferred embodiment, it will be appreciated that modifications and equivalents may occur to one of ordinary skill in the art having the benefits of the teachings of the present invention. It is intended that such modifications shall be included within the scope of the claims which are appended hereto.

WHAT IS CLAIMED:

1. A transmyocardial implant for establishing a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vasculature
5 residing on an exterior of said wall, said implant comprising:

a hollow rigid conduit having a first portion and a second portion, said first portion sized to be received within said lumen and said second portion sized to extend from said vasculature through said myocardium into said chamber, said
10 conduit having open first and second ends on respective ones of said first and second portions to define a blood flow pathway within an interior of said conduit between said first and second ends;

said conduit formed of a conduit material sufficiently rigid to resist
15 deformation and closure of said pathway in response to contraction of said myocardium and said conduit material resistant to thrombus formation;

a tissue growth inducing material secured to an exterior of said conduit.

20 2. A transmyocardial implant according to claim 1 wherein said tissue growth inducing material is spaced from said first and second ends a distance to avoid tissue growth on said tissue growth inducing material from extending over and blocking said first and second ends.

25 3. A transmyocardial implant according to claim 2 wherein said second portion is sized to extend into said chamber beyond said myocardium, said tissue growth inducing material is spaced from said second end.

30 4. A transmyocardial implant according to claim 1 wherein said tissue growth inducing material includes a plurality of fibers defining a plurality of interstitial spaces for receiving tissue growth and said tissue growth inducing material is biocompatible.

5. A transmyocardial implant according to claim 4 wherein said tissue growth inducing material is a polyester fabric.

5 6. A transmyocardial implant according to claim 1 wherein said tissue growth inducing material include a porous layer on said exterior of said conduit.

7. A transmyocardial implant according to claim 1 wherein an external area of said conduit surrounded by said tissue growth inducing material is abraded.

10

8. A transmyocardial implant according to claim 1 wherein said tissue growth inducing material surrounds said second portion and not said first portion.

9. A transmyocardial implant according to claim 1 wherein said tissue
15 growth inducing material surrounds both said second portion and said first portion.

10. A transmyocardial implant according to claim 1 wherein said tissue growth inducing material surrounds said first portion and not said second portion.

FIG. 1





FIG. 1A







FIG. 3





FIG. 3A








FIG. 5



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/17310

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US 5 429 144 A (WILK) 4 July 1995 see column 8, line 1 - line 58; figures 7-9	1,9 4-6
Y	US 5 545 217 A (OFFRAY ET AL) 13 August 1996 see column 2, line 66 - column 3, line 3 see column 4, line 32 - line 40	4-6
A	WO 97 27898 A (TRANSVASCULAR, INC.) 7 August 1997 see abstract; figure 10	1
A	US 5 655 548 A (NELSON ET AL) 12 August 1997	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

*** Special categories of cited documents :**

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

10 December 1998

Date of mailing of the international search report

18/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

SMITH, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/17310

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5429144 A	04-07-1995	US 5409019 A	25-04-1995
		US 5287861 A	22-02-1995
US 5545217 A	13-08-1996	AU 690449 B	23-04-1998
		AU 5385796 A	07-11-1996
		CA 2218497 A	24-10-1996
		EP 0821575 A	04-02-1998
		WO 9632908 A	24-10-1996
WO 9727898 A	07-08-1997	US 5830222 A	03-11-1998
		AU 1847197 A	22-08-1997
		AU 1847297 A	22-08-1997
		AU 1847397 A	22-08-1997
		AU 7431696 A	30-04-1997
		CA 2234361 A	17-04-1997
		EP 0879068 A	25-11-1998
		WO 9713463 A	17-04-1997
		WO 9727897 A	07-08-1997
		WO 9727893 A	07-08-1997
		AU 1275997 A	11-05-1998
		WO 9816161 A	23-04-1998
US 5655548 A	12-08-1997	AU 4352497 A	02-04-1998
		WO 9810714 A	19-03-1998
		US 5824071 A	20-10-1998